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Abstract
The human IgM B7-DC XAb protects mice from tumors in both therapeutic and prophylactic settings. Its mechanism of
action is mediated by its binding to B7-DC/PD-L2 molecules on the surface of dendritic cells (DCs) to induce a
multimolecular cap and subsequent activation of signaling cascades that determine a unique combination of DC
phenotypes. One such phenotype, the B7-DC XAb-induced antigen accumulation in mTLR-matured DCs, has been linked to
signaling through TREM-2, but the signals required for other DC phenotypes critical for the therapeutic effects in animal
models remain unclear. Here, FRET and co-immunoprecipitation studies show that CD40 is recruited to the multi-molecular
complex by B7-DC XAb. Signals emanating from CD40 are important, as CD40
2/2 DCs treated with B7-DC XAb (DC
XAb)
activated DAP12, but failed to activate NFkB, and were not protected from cell death upon cytokine withdrawal or
treatment with Vitamin D3. CD40
2/2 DC
XAb also failed to secrete IL-6 and were unable to support the conversion of T
regulatory cells into IL-17+ effector T cells in vitro. Importantly, the expression of CD40 was required for the overall ability of
B7-DC XAb to induce anti-tumor CTL, to provide protection from a number of tumor types, and for DC
XAb to be effective
anti-tumor vaccines in vivo. These results indicate that B7-DC XAb modulation of DC phenotypes is through its ability to
indirectly recruit common signaling molecules and elements of their endogenous signaling pathways through targeted
binding to a cell-specific surface determinant.
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Introduction
Generation of a vigorous T cell response is dependent on the
activation of the T cells by professional antigen presenting cells and
requires stable pMHC:TCR interaction (signal 1), co-stimulation
through CD28 and other membrane molecules (signal 2), and
secretion of T cell growth factors (signal 3). B7-DC XAb is an IgM
antibody from the serum of a patient with Waldenstrom’s
macroglobulinemia that binds to the surface of mouse and human
DCs [1]. This binding leads to activation of the DCs and an
augmentation of a number of phenotypic functions that are distinct
from those elicited in DCs activated by TLR ligands or CD40L [2].
The pentameric structure of the IgM antibody is mandatory for the
antibody to execute its effect on DCs. Monomers fail to bind and
activate the DC and can prevent DC binding by the pentamer [1].
A candidate gene approach revealed that antibody binding is
dependent on the expression of the co-stimulatory molecule B7-
DC/ PD-L2 [1]. Therefore, we refer to this antibody as B7-DC
cross-linking antibody (B7-DC XAb). Importantly, B7-DC XAb
alsoactivateshumanDC[3]and hasactionsinseveralexperimental
models of cancer in which results from the use of TLR ligands or
TNF family members have been less impressive [4,5].
The B7-DC molecule has a short cytoplasmic tail (5 amino
acids), does not have charged amino acids, and by itself cannot
convey signals from the membrane to the cytoplasm. We have
recently shown that treatment of DCs with B7-DC XAb (DC
XAb)
induces multiple membrane proteins to become organized into a
cell surface cap [3]. These molecules include B7-1 (CD80), B7-2
(CD86), class-II, TREM-2 and CD11c. Stimulation of antigen
accumulation by DC
XAb requires TREM-2 and is mediated by the
activation of DAP12 and Syk. TREM-2 is also required for B7-DC
XAb-mediated tumor protection in mice. However, in subsequent
experiments, we found that TREM-2 was dispensable for the
activation of an NFkB pathway necessary for DC treated with B7-
DC XAb to remain viable under stress [6]. CD40 activation has
been shown to increase the viability of a number of cell types
including dendritic cells, to activate NFkB, and to increase
secretion of a number of cytokines such as IL-1, IL-6 and TNFa
[7–9]. CD40 activation mechanisms can also lead to tumor
immunity [10–12]. Thus, we hypothesized that CD40 may play a
role in some of the phenotype responses observed in DC
XAb.
In this report we show that CD40 is indeed present in a B7-DC
XAb-induced cell surface complex and is required for activation of
NFkB, protection of DC
XAb from cell death signals, and for the
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5373secretion of IL-6. CD40 expression is also required for DC
XAb to
reprogram T regulatory cells to IL-17+ effectors, an outcome of
B7-DC XAb shown previously to break tolerance in an antigen-
specific manner [5]. Finally, presence of CD40 on the DCs in vitro
and in vivo is required for the generation of tumor-specific
cytolytic effector cells and to protect mice from tumors. Thus B7-
DC XAb modulation of DC phenotypes is through its ability to
bind a cell-specific molecule to simultaneously recruit and activate
multiple signaling cascades in a combinatorial manner to directly
regulate DC responses and indirectly regulate T cell functions.
Results
B7-DC XAb induces CD40 recruitment into the multi-
molecular cap on DCs
Previous dissection of the mechanism of the B7-DC XAb
action showed that its binding to DC caused a reorganization of
cell surface molecules (class II, CD80, CD86) into a cap-like
cluster that also contained the signaling molecule TREM-2 [3].
While DCs from TREM-2 knockout mice were not able to
accumulate antigen in response to B7-DC XAb, they were still
able to activate NFkB, a mediator of DC viability following B7-
DC crosslinking. Since CD40 is a known activator of NFkB, we
used FRET analysis to determine whether CD40 was among the
cell surface molecules recruited into the B7-DC XAb-induced cap
on DC. A FRET signal between the PE-labeled anti-CD40 and
APC labeled anti-Class II was detected as early as 5 minutes in
DCs stimulated with B7-DC XAb (Fig. 1A, unfilled histograms).
Thus, B7-DC XAb cross-linked CD40 to a previously identified
constituent of the cell surface cap. The signal was maintained for
as long as 30 minutes, but no FRET signal was detected upon
stimulation with control antibody (filled histograms). To directly
demonstrate that CD40 molecules were present in a multi-
molecular complex, we performed Western blots on MHC class
II immunoprecipitates. CD40 was detected in MHC class II
complexes isolated from the DCs stimulated with B7-DC XAb
but not from DCs stimulated with control antibody (Fig. 1B).
Taken together, these data suggest that CD40 is recruited into the
multimolecular cap that forms on DCs upon treatment with B7-
DC XAb.
CD40 is required for NFkB activation in DC treated with
B7-DC XAb
Activation of CD40 culminates in stimulation of NFkBi n
multiple cell types [8,13,14]. Since CD40 was found to complex
with class II, we asked whether CD40 mediated NFkBa c t i v a t i o n
in DC
XAb. Bone marrow derived DCs from wild type, CD40
2/2,
or TREM2
2/2 mice were stimulated with control antibody or
B7-DC XAb for 15 minutes. In addition, parallel CD40
2/2 DC
were stimulated with anti-CD40 or the TLR4 agonist, LPS. Cells
were permeabilized and stained with an antibody that recognizes
only the activated NFkB complex [6] and visualized by confocal
microscopy. Abundant nuclear fluorescence (FITC-anti-p65
alone, upper left panels; merged with DAPI, lower panels) shows
that NFkB was activated in wild type and TREM2
2/2 DCs
stimulated with B7-DC XAb but not in CD40
2/2 (KO) DC
stimulated with B7-DC XAb, or anti-CD40 antibody (Fig. 2A).
However, CD40
2/2 DC still activated NFkB when stimulated
through TLR4. Control antibody treatment failed to activate
NFkB in all groups of DCs. The CD40
2/2 DCs activated
DAP12 and Syk kinase upon B7-DC crosslinking (Fig. 2B),
underscoring these cells were only non-responsive to CD40-
dependent signals.
CD40 is important in promotion of B7-DC cross-linking
Ab-induced DC survival under adverse conditions
CD40-CD40L interaction has been shown to promote survival
of a number of cell types [15,16]. Since CD40 was shown to be
present in the cell surface complex that forms after cross-linking
B7-DC on DCs, we tested whether CD40 was required for the
enhanced survival previously observed in DC
XAb [6]. Bone
marrow derived DCs from wild type or CD40
2/2 mice were
matured with CpG then treated with the cell death inducer
Figure 1. CD40 is rapidly recruited into complexes containing
MHC MHC class II on dendritic cells treated with B7-DC XAb. (A)
DCs were pre-stained with APC-labeled antibody against MHC class II
and PE-labeled antibody against CD40 for 15 min. An aliquot of cells
was analyzed by flow cytometry (0 min time point). The remaining cells
were then treated with 10 mg/ml IgM control antibody (filled
histograms) or B7-DC XAb (open histograms). Cells were sampled at
the indicated time points and analyzed for a FRET (FL3 channel). (B)
Lysates were prepared from untreated DC (09) or DC treated with
control antibody or B7-DC XAb for the indicated times and subjected to
immunoprecipitation using an antibody against MHC class II. The
resultant complexes were resolved by SDS-PAGE, transferred to PVDF
membrane, and probed for CD40. IgH serves as a loading control. The
results shown are representative of 2 experiments.
doi:10.1371/journal.pone.0005373.g001
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determine viability (expressed as mean relative fluorescence). Wild
type DCs that received B7-DC XAb remained viable in the
presence of Vitamin D3 while control antibody failed to protect
wildtype DC (Fig. 2C). The effect of B7-DC XAb was dependent
on presence of CD40, as DCs that lacked CD40 were not
protected from this cell death pathway (Fig. 2C). Wild type or
CD40
2/2 DC were also tested for B7-DC XAb-induced survival
when deprived of GM-CSF/IL-4 cytokines for 24 hours. Only
wild type DCs treated with B7-DC cross-linking Ab were able to
survive cytokine withdrawal, and B7-DC XAb treatment was
unable to promote cell survival in CD40
2/2 DCs. However,
CD40
2/2 DC were still protected cells from cytokine withdrawal
if stimulated with RANK ligand, another known activator of
NFkB and downstream pro-survival signals (Fig. 2D). CD40
ligation has been demonstrated to activate ERK, and activation of
ERK promotes cell survival. Therefore, we tested the requirement
for CD40 in ERK activation in response to B7-DC XAb. Wild-
type DCs, but not CD402/2 DCs, exhibited ERK activation in
response to B7-DC XAb cross-linking, (Figure 2B). Both groups of
DCs activated ERK in response to TLR4 ligation. These findings
demonstrate that CD40 is an essential upstream mediator of ERK
Figure 2. DCs require CD40 for B7-DC XAb mediated NFkB activation and protection from cell death. (A) NFkB activation in wild type
(WT), CD40
2/2 or TREM2
2/2 (KO) DC was determined after 15 min stimulation with control antibody, B7-DC XAb, anti-CD40, or LPS (TLR4 ligand).
Cells were fixed, stained and imaged using a confocal microscope. Upper left panels show FITC-anti-p65 staining, upper right panels show DAPI
staining of nuclei, lower panels show merged images of the upper panels. (B) Wild-type or CD40
2/2 (KO) DC were treated with control antibody or
B7-DC XAb for 5 min. DAP12- (left) or Syk- (middle) specific immunoprecipitates or whole cell lysate for ERK (right) were resolved and blotted using a
phosphotyrosine-specific antibody. IgH or total ERK serves as a loading control. (C) Cell death was induced in wild type (filled bars) or CD40
2/2 (open
bars) DC by treatment with vitamin D3. All cultures were subsequently incubated with Alamar Blue Dye. Cell viability was measured using a
fluorescence plate reader after 24 hours and is expressed as relative fluorescence units (RFU). (D) Similar to (C) except cell death was induced by
cytokine withdrawal. Wild type (filled bars) or CD40
2/2 (open bars) DC were cultured in the presence or absence of GM-CSF and IL-4 (+ or 2
Cytokine) for 24 h in the presence of 10 mg/ml control antibody, B7-DC XAb, anti-MHC class II IgM antibody 25-9-3, or the combination of 1 mg/ml B7-
DC XAb and 0.1 mg/ml RANKL as indicated. The results shown are representative of 2 experiments.
doi:10.1371/journal.pone.0005373.g002
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CD40 to the enhanced survival phenotype observed in DC
XAb.
Moreover, this pathway is distinct from the TREM2 pathway used
by DC
XAb to accumulate antigen.
CD40 is necessary for IL-6 secretion by DC
XAb and
reprogramming of Tregs to IL-17+ effectors
Treatment of DCs with B7-DC XAb leads to the production of
IL-6 and IL-6-dependent conversion of T regulatory cells to IL-
17+ effectors [5]. Blockade of NF-kB activation also prevents the
secretion of cytokines including IL-6 from DC
XAb [6]. Thus, we
sought to determine if these two responses of DC to B7-DC XAb
were linked through a requirement for CD40. Wild type or
CD40
2/2 DCs were stimulated with control antibody or B7-DC
XAb for 48 hours and the amount of IL-6 in the culture
supernatants was determined by ELISA. Parallel cultures were
stimulated with CD40 or TLR agonists. Wild type DCs secreted
IL-6 when stimulated with B7-DC XAb or control stimuli
targeting CD40 or toll-like receptors. Neither DC type secreted
IL-6 when treated with control antibody. Importantly, CD40
2/2
DCs did not secrete IL-6 when treated with anti-CD40 or B7-DC
XAb antibodies, but were still able to respond to TLR stimulation
(Fig. 3A).
As a final test for the role of a CD40-NFkB-IL-6 pathway in the
conversion of Tregs to T effector cells [5], wild type or CD40
2/2
DC were pulsed with ovalbumin and treated with the control
antibody or B7-DC XAb. These DCs were then used in vitro as
stimulators of cultures enriched for either CD4
+ CD25
+ Tregs or
CD4
+ CD25
2 non-Tregs isolated from DO11.10 TCR transgenic
mice. After 48 hours, cells from each group were subjected to
intracellular staining for the Treg specific transcription factor FoxP3
andtheTh17specificeffectorcytokineIL-17A.Non-Tregsthatwere
stimulated with antigen-pulsed wildtype or CD40-deficient DC
cntrl
or DC
XAb did not express FoxP3 or IL-17A (Fig. 3B). Tregs
stimulated with antigen-pulsed wild type DC
XAb downregulated
FoxP3 and expressed IL-17A. CD40
2/2 DC
XAbsd i dn o tm e d i a t e
the conversion of T regulatory cells to IL-17+ effector cells (Fig. 3C)
suggesting the necessity of IL-6 inthisprocess. Wild type DC
cntrl and
CD40
2/2 DC
cntrl also failed to cause T regulatory conversion to T
effector cells. However, it is possible that IL-6 alone is not sufficient
for inducing DC
XAb mediated T regulatory cell conversion into
effector cells. To test this, DC
cntrl,D C
XAb,C D 4 0 2/2
cntrl,
CD402/2DC
XAb, IL-62/2
cntrl and IL-62/2DC
XAb were
analysed for their potential to induce T regulatory cell conversion
by exogenous addition of IL-6. As shown in panels 3D and E, under
culture conditions where the DCs are defective in making IL-6 (both
IL-62/2 DCs and CD402/2DCs), provision of IL-6 restored the
induction of Th17 cells, whereas the CD40 deficient and IL-6
deficient DC
cntrl supplemented with IL-6 failed to induce IL-17A+
cells. This data indicate IL-6 is necessary, but not sufficient to cause
T regulatory cell conversion to Th17 cells, highlighting the
importance of other factors induced by B7-DC cross-linking in
these regulatory events.
We have previously shown that DC
XAb-mediated conversion of
Tregs into IL-17+ effectors occurs in the absence of any significant
cell proliferation [5]. Since the data in Fig. 3B show that non-
Tregs did not express IL-17A after stimulation with DC
cntrl or
DC
XAb, we conclude that the IL-17A expressing cells originated
from Tregs and were not a product of outgrowth of contaminating
non-Tregs. These data show that CD40 is necessary for DCs to
not only respond to B7-DC XAb by secreting IL-6, but also to
induce the concomitant conversion of T regulatory cells into
effector cells.
CD40 is important for the generation of anti-tumor T cell
responses induced by B7-DC XAb
A major response in mice receiving B7-DC XAb is the
induction of a potent CTL response that drives the protection of
those mice from a lethal melanoma challenge [18,19]. To test the
ability of the B7-DC XAb to confer protection against other tumor
types, we injected cells derived from kidney, thymus, or breast
tumors or leukemia or melanoma cells into genetically-matched
hosts. Mice receiving each tumor type also received either control
antibody or B7-DC XAb treatment. Nearly all of the mice (97%)
that were treated with the control antibody succumbed to the
tumor burden irrespective of the origin of the tumor or the tumor-
host combination. Anti-tumor immunity was produced by B7-DC
XAb treatment in either strain of mice tested and was also
independent of tumor type (Table 1).
CD40 has been shown to play a major role in cross-presentation
of antigens to stimulate CD8 T cells [20], and anti-CD40 antibody
treatment has been used to induce protection against tumors
[10,21]. Therefore, we analyzed the role of CD40 in the anti-
tumor immunity elicited by B7-DC XAb in two tumor models.
Wild type or CD40
2/2 mice were implanted with B16 melanoma
or WEHI-3 leukemia cells and treated systemically with the
control antibody or B7-DCXAb. On day 7, lymph node cells were
isolated from some of the treated mice and used as effectors against
51Cr-labeled B16 or WEHI-3 targets. EL-4 or P815 cells served as
MHC-matched negative controls. In the CD40
2/2 mice, potent
effectors were not induced in response to B7-DC XAb treatment
(Fig. 4). Moreover, when the remaining mice were followed for up
to 90 days, we found that all the groups of mice succumbed to the
tumor except the wild type mice receiving B7-DC XAb (Table 2).
These data suggest that CD40 is necessary for the generation of
the potent anti-tumor immunity induced by B7-DC XAb.
Since CD40 is expressed on multiple cell types, we asked
whether the expression of CD40 on DC alone was critical for B7-
DC XAb-induced anti-tumor immunity. To test this, bone
marrow-derived wild type or CD40
2/2 DCs were pulsed with
B16 melanoma tumor cell lysate and treated with control antibody
or B7-DC XAb. After overnight incubation, the DCs were
adoptively transferred into normal mice as a vaccine. Mice were
then implanted with live B16 tumor. The animals were followed
for 90 days for the development of tumor. Whereas mice receiving
wild-type DC
XAb vaccine were protected from melanoma
challenge, animals receiving the CD40
2/2 DC
XAb succumbed
to the tumor (Table 3). Taken together, these data show that
CD40 on DC is critical for B7-DC XAb to confer tumor immunity
in vivo.
Discussion
Cross-linking dendritic cells with B7-DC XAb results in a
number of phenotypic changes, including enhanced survival,
increased ability to accumulate antigen, enhanced ability to
activate naı ¨ve T cells, increased efficiency of seeding draining
lymph nodes, and the up-regulation of key immunomodulatory
cytokines [2,22–24]. B7-DC has no known ability on its own to
transduce an intra-cellular signal. Therefore, we have focused on
delineating the events that occur on the surface of the DCs upon
binding of B7-DC XAb and to determine what membrane and
intracellular molecules mediate the various DC phenotypic
responses. Previously, we found that cross-linking B7-DC induced
a substantial reorganization of cell surface molecules, resulting in
the clustering of MHC, CD80, CD86, and CD11c molecules into
a cap [3]. In this report we document that CD40 is also present
within this cell surface complex on DC
XAb. The recruitment of
CD40 Mediated Treg Conversion
PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5373Figure 3. DCs require CD40 in order to secrete IL-6 and convert Tregs to Th17 cells in vitro. (A) IL-6 was measured in culture supernatants
of wild type or CD40
2/2 (KO) DC stimulated for 48 h with control antibody, B7-DC XAb, anti-CD40 or TLR agonists as indicated. Statistical analysis was
performed using one-way ANOVA. IL-6 secreted by WT DCs stimulated with B7-DC XAb was significantly higher than IL-6 secreted by WT DCs
stimulated with control antibody; IL-6 secreted by wild type or CD40
2/2 DC in response to TLR ligands was significantly higher than IL-6 induced in
WT DC by B7-DC XAb (p,0.01). Error bars represent the standard deviation from the mean of triplicate cultures. (B) Enriched populations of DO11.10
CD40 Mediated Treg Conversion
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NFkB and protection of DC from cell death signals, a response
also linked to the secretion of cytokines such as IL-6. Moreover,
CD40 expression is required for DC
XAb-induced conversion of T
regulatory cells to IL-17-producing effector cells in vitro and the
induction of CTLs capable of conferring tumor-protective
immunity in mice. However, under culture conditions where the
DCs are compromised in their ability to secrete IL-6 in response to
B7-DC XAb treatment, addition of exogenous IL-6 resulted in
generation of IL-17 cells, albeit at a lesser frequency. Antigen
presentation by DC
cntrl in the presence of exogenously added IL-6
fail to induce Treg conversion. This implies that apart from IL-6,
other unknown factors from DCX
Ab are necessary to cause
complete conversion of T regulatory cells. Taken within the
context of our previous finding that TREM-2 recruitment on
DC
XAb mediates the induction of antigen accumulation by mature
DC [3], we conclude that B7-DC XAb has its many unique
biologic effects due to its ability to specifically target the surface of
DC, recruit, and activate common signaling pathways in DC that,
in turn, modulate multiple T cell functions.
Table 1. B7-DC XAb Induces Protective Immunity Against a Variety of Different Tumor Grafts.
Tumor Number of Cells Mouse Strain
Number of Mice Tumor Free/
Total (Control Ab)
Number of Mice Tumor Free/
Total (B7-DC XAb) p Value
B16 5610
5 C57BL/6 0/5 23/23 ,0.001
RENCA 10
6 C57BL/6 0/9 9/9 ,0.001
EL4 5610
5 C57BL/6 0/8 8/8 ,0.001
WEHI-3 5610
3 BALB/c 1/5 6/6 0.015
TUBO 5610
5 BALB/c 0/5 10/10 ,0.001
Mice received B7-DC XAb or control antibody (i.v.) at the time they were grafted with tumor cells (s.c.). Mice were monitored regularly for tumor growth and were
euthanized if tumors reached 17617 mm. Mice remaining tumor-free were monitored regularly for up to 30 days; TUBO mice were monitored up to 300 days. The
scores indicate the number of mice in the indicated treatment group remaining free of tumor.
doi:10.1371/journal.pone.0005373.t001
Figure 4. CD40 is required for the DC
XAb-induced generation of anti-tumor CTL responses in vivo. Wild type or CD40
2/2 mice were
engrafted with B16 melanoma (A) or WEHI-3 leukemia (B) and treated intravenously with 30 mg B7-DC XAb or control antibody. On day 7, cells from
draining lymph nodes were used as effectors in CTL assays. (A) CTL against
51Cr-labeled B16 tumor targets (Left) or unrelated EL-4 controls (Right).
Filled squares show CTL for wild-type mice receiving B7-DC XAb. (B) CTL against
51Cr-labeled WEHI-3 tumor targets (Left) or unrelated, MHC-matched
P815 controls (Right). Filled triangles show the CTL response from wild type mice receiving B7-DC XAb. Symbols and lines for all other treatment
groups are nearly superimposable. The results shown are representative of 2 experiments.
doi:10.1371/journal.pone.0005373.g004
non-Tregs or Tregs (.95% pure) were cultured with OVA-pulsed and control- or B7-DC XAb-treated DC isolated from wildtype, (C and E) CD40
2/2
mice and (D) IL-62/2 mice. After 48 h, expression profiles for FoxP3 and IL-17A were determined by intracellular staining and flow cytometry. All
experiments were conducted at least twice.
doi:10.1371/journal.pone.0005373.g003
CD40 Mediated Treg Conversion
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similarities to DC activated by other means, but there are key
differences. Typically, stimulation through TNFR, CD40, or TLR
as well as through TREM-2 results in a maturation response in
DC, which is associated with the up-regulation of CD80, CD86,
and MHC class II and a decrease in antigen uptake [25,26].
However, DC
XAb do not exhibit this classic ‘‘mature’’ phenotype.
In fact, B7-DC XAb causes matured DC to regain the ability take
up antigen [2], and it stimulates antigen presentation by immature
DC [27]. B7-DC cross-linking has little effect on the levels of class
II, CD80, and CD86, but upregulates CCR7 expression. CD40
ligation typically down-regulates TREM-2 [28], but our studies
show that B7-DC XAb co-opts both CD40 and TREM-2 signals.
Many TLR and TNFR family members activate NFkB through
MyD88 [29] whereas B7-DC XAb activation of NFkB is MyD88-
independent [6]. Other cell surface receptors present on DC
(TLRs, CD80, CD86, and TREM-1) can activate NFkB [29], but
experiments with CD40
2/2 DC suggest that CD40 is the one
required by B7-DC XAb. TREM-2 binds DAP12 to activate Syk.
Stimulation of DC via TREM-2 also induces a maturation
response and activates ERK [25]. B7-DC XAb activates ERK, but
ERK is not involved in the TREM-2 mediated response of DC to
B7-DC XAb [3]. However, ERK activation was dependent on the
expression of CD40 on the dendritic cells activated with B7-
DCXAb. These findings suggest that the combined signals from
CD40 and TREM-2 upon B7-DC cross-linking are different than
when either signal is generated through traditional means, or that
each of these signals (and perhaps other signals not yet delineated)
are only partially ‘‘on’’ in DC
XAb.
Thus, fundamental to the mechanism of action of B7-DC XAb
is its ability to activate CD40 and TREM2 pathways in an
indirect, but DC-specific manner. Cell-specific activation of
multiple pathways is potentially advantageous from a therapeutic
perspective, especially when it can be induced with a single
reagent. Furthermore, B7-DC XAb is effective as a modulator of
T cell functions in animal models, even in the absence of ex vivo
manipulations. Teasing out additional details in the signals
emanating from B7-DC XAb will be critical to furthering our
understanding of how of this novel immune modulator works. For
example, various TNF receptor associated factors (TRAFs)
mediate a diverse array of events downstream of CD40 and
related receptors [30]. A role for TRAFs in DC
XAb remains to be
tested. Whether B7-DC XAb also activates other kinases that
regulate NFkB (e.g., pim1 dependent kinase, [31]) is not known.
Whether B7-DC XAb affects cIAP, Bcl molecules, or additional
survival-promoting pathways is also not known.
The net effect of using this reagent in animal models is an
antigen-specific modulation of immune responses resulting in the
alleviation of allergic responses, the clearance of tumors, and the
induction of specific autoimmunity [4,5,18,19,32]. Studies with
B7-DC XAb have provided new insights into the plasticity of T
cell lineages and have expanded the potential of immune-based
therapies to impact disease. In this regard, we have shown that B7-
DC XAb also activates human DC [6], allowing for results in
mouse models to be rapidly translated into the clinic. Generation
of such highly antigen specific immunity in the absence of
autoimmunity with B7-DC XAb [5] suggests a hypothesis that
IgM-based therapeutic antibodies provide a way to induce the
integration of complex signals in a cell-specific manner. Testing of
this hypothesis and translation of B7-DC XAb to treat human
cancers is now underway.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
Institutional Animal Care and Use Committee of Mayo Clinic
(protocol numbers A10306, A207, and A33403).
Table 2. B7-DC XAb-induced Tumor Protection is Dependent on CD40.
Tumor Mouse Strain
Number of Mice Tumor
Free/Total (Control Ab)
Number of Mice Tumor
Free/Total (B7-DC XAb) p Value
B16 B6 WT 0/8 8/8 ,0.001
B16 CD402/2 0/8 0/8 n.s.
WEHI BALB/cWT 0/3 5/5 ,0.001
WEHI CD402/2 0/7 0/8 n.s.
Wild type or CD402/2 mice were implanted with B16 or WEHI tumor (5610
5 cells) and received control antibody or B7-DC XAb by intravenous administration. The
mice were monitored for tumor growth and were euthanized if tumor size reached 17617 mm. Tumor-free B16-implanted mice were monitored regularly for more than
90 days; tumor-free WEHI-implanted mice were monitored regularly for more than 60 days. The scores indicate the number of mice in the indicated treatment group
remaining free of tumor. n.s.=not significant.
doi:10.1371/journal.pone.0005373.t002
Table 3. DC
XAb Vaccination Requires CD40 for Tumor Immunity.
Tumor Mouse Strain
Number of Mice Tumor
Free/Total (Control Ab)
Number of Mice Tumor
Free/Total (B7-DC XAb) p Value
B16 WT 0/4 4/4 0.029
B16 CD402/2 0/4 0/4 n.s.
Normal mice received 2610
6 wild-type or CD40
2/2 DC pulsed with B16 tumor lysate and control antibody or B7-DC XAb as indicated. On the same day, 5610
5 B16
tumor cells were implanted on the right flank. The animals were monitored for tumor growth for at least 90 days and were euthanized if the tumor reached 17617 mm.
The scores indicate the number of mice in the indicated treatment group remaining free of tumor. n.s.=not significant.
doi:10.1371/journal.pone.0005373.t003
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C57BL/6J mice, BALB/CJ mice, DO11.10 mice, CD40
2/2
mice, and IL-6
2/2 mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Male mice were used, and all
experiments were conducted with IACUC oversight. The B16
melanoma cell line was kindly provided by Dr. Richard Vile
(Mayo Clinic, Rochester, MN) and the RENCA cell line was
kindly provided by Dr. Eugene Kwon (Mayo Clinic, Rochester,
MN). EL-4 and WEHI-3 lines were purchased from American
Type Culture Collection (ATCC, Vanassas, VA). The TUBO cell
line, derived from a spontaneous breast carcinoma in a Balb-neuT
mouse [33], was a gift from Dr. Esteban Celis (Moffitt Cancer
Center, Tampa, FL). All tumor cell lines were maintained in
DMEM (Life Technologies Invitrogen) containing 10% cosmic
calf serum (Hyclone). Anti-mouse CD4-PE (RM4-5), MHC class II
specific IgM (25-9-3), and purified anti-mouse MHC class II(M5/
114.15.2) were purchased from BD Biosciences (San Jose, CA).
APC-coupled FoxP3 antibody (FJK-16s), anti-mouse IL-17A-PE
(eBio17B7) and purified and PE-coupled anti-mouse CD40 (IC10)
and APC-coupled anti-mouse MHC class II antibody (M5/
114.15.2) were purchased from eBioscience (San Diego, CA).
Antibody against Syk kinase (4D10) and ERK (C.14) was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-
tyrosine (4G10), anti phospho ERK (9101) and Goat anti-mouse
antibodies were obtained from Upstate Cell Signaling Solutions
(Lake Placid, NY). Rabbit antibody against DAP12 (MC457) was
developed by Dr. Paul Leibson (Mayo Clinic, Rochester, MN).
Protein A-Sepharose was purchased from Pierce Biotechnology
(Rockford, IL). For analysis of co-precipitating signaling molecules,
affinity purified antibody against mouse Class II (I-A
b) (KH74) (BD
Biosciences, San Jose, CA) was used. Vitamin D3 (1a, 25-
dihydroxyvitamin D3) was a gift from Dr. Matthew Griffin (Mayo
Clinic, Rochester, MN). Receptor activator of the NF-kB (RANK)
ligand was purchased from Chemicon International. The TLR
ligands were used at 10 mg/ml and were as follows: TLR2 ligand,
Pam3CSK4 (InVivogen); TLR3 ligand, polyI:C (Calbiochem);
TLR 4 ligand, LPS (Sigma); TLR7/8 ligand, Gardiquimod
(InVivogen); TLR9 ligand, CpG (synthesized in Mayo core
facility).
B7-DC XAb
The human monoclonal IgM antibodies B7-DC XAb
(sHIgM12) and isotype-matched control (sHIgM39) were identi-
fied in a screen for mouse DC-binding antibodies present in a bank
of serum samples from patients with monoclonal gammopathies.
The DC-binding sHIgM12 antibody and the non-binding
sHIgM39 control antibody and were purified as described [1].
Because of the dependence on B7-DC for its biologic properties,
the requirement for the pentameric form, and the observed signals
in DC elicited by antibody binding, we refer to sHIgM12 as B7-
DC cross-linking antibody (B7-DC XAb).
Flow Cytometry and Fluorescence Resonance Energy
Transfer (FRET)
Flow cytometry was used to quantify close molecular interac-
tions on the cell surface as described previously [34]. Briefly,
mouse DC were stained with anti-Class II-APC (M5/114.15.2)
and anti-CD40-PE (IC10). All staining was for 15 minutes. Cells
were stimulated with 10 mg/ml control antibody or B7-DC XAb
or purified anti-mouse MHC class IIIgM (25-9-3) and aliquots
from different groups were taken at different time points. The cells
were washed and fixed in 2% paraformaldehyde prior to analysis
by FACS performed by the Mayo Flow Cytometry Core Facility
using a FACSCaliber (BD Biosciences, Franklin Lakes, NJ). FRET
(upon excitation of PE at 488 nm and emission of APC at 660 nm)
was visualized in FL3 channel (650–670 nm LP). Data collected as
log10 fluorescence were analyzed using CellQuest (BD Bioscienc-
es). MFI=Mean Fluorescence Intensity.
Isolation of Tregs and non-Tregs
Splenocytes were isolated from pooled spleens harvested from
three mice. Tregs were isolated by positive selection using Mouse
Treg Isolation kit from Miltenyi Biotec (Auburn, CA), as per the
manufacturer’s protocol [5]. Briefly, splenocytes were incubated
with anti-CD25 antibody coupled to magnetic beads for 15 min
prior to binding to the MACS column. Cells that were not bound
were washed three times with RPMI/10% FBS and used as non-
Tregs. Adherent cells (Tregs) were eluted and washed prior to use.
In vitro activation of Tregs and non-Tregs
Bone marrow derived WT or CD40
2/2 immature DCs (2610
6)
were pulsed with antigen and treated with control antibody or B7-
DC XAb overnight then used to stimulate naı ¨ve DO11.10 Tregs
in culture (together in 24-well plates) at a 1:1 ratio in vitro for
48 hours. After 48 hours, cells were removed, pooled, and
prepared for analysis by intracellular staining for the expression
of FoxP3 and IL-17A. In some experiments, 20 ng/ml of IL-6
(R&D Systems, Minneapolis) was added at the start of the culture.
Briefly, cells were permeabilized with CytoFix/CytoPerm kit (BD
Biosciences, San Diego, CA) and incubated with the appropriate
conjugated antibody at 4uC according to the manufacturers’
suggestions prior to analysis by flow cytometry as described [5].
Generation of bone marrow DCs
DCs were generated from the mouse bone marrow [35]. Bone
marrow cells were plated (1610
6/ml) in RPMI /10% serum
containing 10 mg/ml of murine GM-CSF and 1 ng/ml of murine
IL-4 (PeproTech, Rocky Hill, NJ). The culture medium was
changed on day 2. DCs were used on day 6 unless otherwise
indicated. For adoptive transfer experiments, day 6 DC were
pulsed with antigen (1 mg/ml) and isotype control antibody or B7-
DC XAb (10 mg/ml) overnight and injected into mice the
following day.
Confocal microscopy
Wild type or CD40
2/2 DC were stimulated with 10 mg/ml of
Ab or TLR ligand for 15 minutes, fixed and permeablized using
Cytofix/Cytoperm kit (BD Pharmingen). Subsequently, Ab against
a C-terminal peptide of NFkB was added followed by anti-rabbit
FITC. Nuclei were stained with DAPI (Sigma-Aldrich) before
being observed with a LSM510 laser scanning confocal micro-
scope (Carl Zeiss) at 406magnification and LSM510 software was
used for the analysis.
Cell viability assay
Wild type or CD40
2/2 DCs were tested for their viability in a
cytokine-deprived environment as previously described [6]. In
brief, day 5 DCs were plated in triplicate into 96-well plates
(2610
4 cells/well) in RPMI 1640 without serum, GM-CSF, or IL-
4 and in presence of B7-DC XAb, isotype control Ab, or RANK
ligand (10 mg/ml). For experiments using vitamin D3 to induce cell
death [17], DCs were matured with 200 ng/ml CpG plus 10 nM
vitamin D3. All cultures were maintained overnight then Alamar
Blue (Biosource International) was added to a final concentration
of 10% (v/v). Readings were taken after additional 24 h of culture
using a Spectra Max M2 Multi Detection Reader (Molecular
CD40 Mediated Treg Conversion
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emission reading of 590 nm.
Tumor experiments
All in vivo tumor experiments were carried out as previously
described [19]. Briefly, mice (wild-type or CD40
2/2) were injected
with the indicated number of tumor cells in the right flank, and
received control antibody or B7-DC XAb (30 mg) by intravenous
administration. The mice were monitored regularly for tumor
growth. To assess CTL responses, draining lymph node cells (from
2 mice in each group) were harvested on day 7, pooled, and used
as effectors against the
51Cr-labeled B16 melanoma or WEHI-3
target and EL4 or P815 control cells. The remaining mice were
monitored for tumor growth for the times indicated. For
experiments using adoptive transfer of DC, mice received B16
melanoma lysate-pulsed wild type or CD40
2/2 dendritic cells
(2610
6, intraperitoneally) pretreated overnight with 10 mg/ml
control antibody or B7-DC XAb. In all experiments, mice bearing
tumors of size 17617 mm were euthanized as per the Institutional
Animal Care and Use Committee recommendations. Fisher exact
probability test analyses were conducted using SigmaPlot software.
IL-6 ELISA
Bone marrow-derived DC from wild type or CD40
2/2 mice
(1610
6 DC/well) were stimulated for 48 h with 10 mg/ml B7-DC
XAb, control antibody, anti-CD40 antibody, or TLR ligand.
Murine IL-6 was detected in culture supernatants using Ready-
Set-Go ELISA kits from e-bioscience (San Diego, CA, USA) as per
the manufacturer’s instructions. Samples were run in triplicate and
values are recorded as mean6standard error of the mean.
Statistical analysis was performed by one-way ANOVA using
Sigma Stat software.
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